Private Advisor Group LLC Has $1.29 Million Stake in Hologic, Inc. (NASDAQ:HOLX)

Private Advisor Group LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,931 shares of the medical equipment provider’s stock after acquiring an additional 1,278 shares during the period. Private Advisor Group LLC’s holdings in Hologic were worth $1,293,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in the company. Swedbank AB lifted its position in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after buying an additional 306,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Hologic by 25.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,114 shares of the medical equipment provider’s stock worth $1,706,000 after purchasing an additional 4,314 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in Hologic by 55.1% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 7,449 shares of the medical equipment provider’s stock valued at $607,000 after acquiring an additional 2,645 shares during the period. abrdn plc raised its stake in shares of Hologic by 5.2% in the third quarter. abrdn plc now owns 384,022 shares of the medical equipment provider’s stock valued at $31,123,000 after purchasing an additional 18,830 shares in the last quarter. Finally, Integrated Advisors Network LLC raised its stake in shares of Hologic by 17.8% in the 3rd quarter. Integrated Advisors Network LLC now owns 5,543 shares of the medical equipment provider’s stock valued at $452,000 after buying an additional 838 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HOLX. Morgan Stanley lowered their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Evercore ISI decreased their price target on Hologic from $76.00 to $73.00 and set an “in-line” rating on the stock in a research note on Thursday, February 6th. JPMorgan Chase & Co. increased their price objective on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, UBS Group boosted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Hologic Stock Performance

HOLX stock opened at $63.21 on Friday. Hologic, Inc. has a twelve month low of $62.69 and a twelve month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market cap of $14.18 billion, a P/E ratio of 19.94, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The business’s fifty day moving average is $69.33 and its 200-day moving average is $76.10.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.